Mechanisms and Control of Protein Translation in the Kidney

Valerie Schaefferb, c Christine K. Abrassa, c, d

a Primary and Specialty Care Medicine, and b Research and Development Service, Department of Veterans Affairs Puget Sound Health Care System, c Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, and d Allergy and Inflammation Program, UW Medicine Lake Union, Seattle, Wash., USA

Key Words
Protein synthesis · Translational control · mTOR · MicroRNA · Nephropathy · Diabetic nephropathy · Renal cancer · Polycystic kidney disease · Nephritis

Abstract
Translational control of protein synthesis is critical for cell division, homeostasis and survival. Recent data indicate that dysregulation of protein synthesis that leads to either increased or decreased expression of specific proteins contributes to the manifestations of various kidney diseases. Most of the control of protein synthesis occurs in the first or initiation phase, which is also the most complicated. Following the initiation phase is the elongation phase where the peptide chain is formed. RNA transcripts are released from ribosomes after the termination phase. Transcripts can be translated in a cap-dependent or cap-independent manner. The mTOR (mammalian target of rapamycin) cascade regulates translation of most cap-dependent transcripts at the level of initiation and elongation, which represents 95% of total transcripts. During specific events (e.g. mitosis, stress cell survival) control of the less-common cap-independent transcripts occurs which allows the cell to adapt to the new state. Activation of stress kinases and inactivation of the mTOR pathway are at the center of this adaptive mechanism. Recent studies have elucidated the role of micro-RNAs (miRs) in controlling translation. miRs bind directly to specific transcripts and most often directly reduce translation; however, by targeting other positive or negative regulators of the pathways regulating protein synthesis they may indirectly affect synthetic levels of other transcripts. Several examples are described below in which these mechanisms are intertwined and act together to dysregulate protein synthesis in the diseased kidney.

Introduction

During the last decade, sequencing of the human genome has focused research efforts on understanding mechanisms that control gene transcription. As these approaches have grown in sophistication and whole transcriptomes have been correlated with protein levels, it has become apparent that translational control also plays a critical role in determining the final proteome. After production of a mature mRNA, several critical steps control the amount of protein that is made. Control of protein translation has emerged as an important aspect in cell homeostasis and survival, and is critically important to the expression of about 25% of proteins expressed by individual cells. Translation of mRNA into protein is primarily regulated at the initiation phase where mecha-
Mechanisms are in place to ensure that changes are implemented rapidly in response to stimuli. In particular, general cap-dependent translation, which concerns about 95% of the transcripts, is often inhibited in cases of stress, whereas cap-independent transcript translation is increased, producing specific proteins needed for the cell survival. In addition, this process allows the cell to conserve energy. Other levels of control, including micro-RNAs (miRs) and stress-kinase activation, converge to modulate the final amount and composition of proteins that are synthesized [1, 2]. These different systems can work together to arrest translation in case of acute stressors, or become dysregulated in the presence of persistent stressors and thereby contribute to disease. In each case, the composition of the proteome is changed with functional consequences. The complex series of control points provides fine-tuning that is necessary for appropriate cell function, but this also provides many points at which disease-associated alterations can impact protein expression and influence disease pathogenesis. The final proteome also takes in account changes in degradation processes. This review will summarize what is currently known about mechanisms of control of protein translation, and describe examples in which alterations in these pathways are relevant to kidney diseases.

### General Mechanism of Translation

Gene expression starts with production of a RNA transcript from a DNA template and its processing in the nucleus followed by translation of mature mRNA in the cytosol into a functional protein product. Although the composition of the transcriptome is controlled by transcription, ultimately protein composition is defined by the rate of translation. Traditionally, translation is divided into three steps: initiation, elongation and termination, with translation initiation often being the limiting step.

#### Initiation Phase

About 95% of total cellular mRNAs are translated in a cap-dependent fashion where the 40S ribosome subunit is recruited to the canonical m^7^GpppN (7-methyl guanosine) cap at the 5’ end of the mRNA with the pre-initiation complex (PIC). In addition to the 40S ribosomal subunit, the PIC is composed of several eukaryotic initiation factors (eIFs), including eIF1, eIF1A, eIF2, the methionyl initiator tRNA, eIF3, eIF5 and the cap-binding factor, eIF4E, and GTP (guanosine-5’-triphosphate) (fig. 1) [3]. Once the PIC is assembled, it migrating linearly along the RNA from 5’ to 3’ until it recognizes the initiation codon (AUG). After recognition, hydrolysis of the GTP bound to eIF2 is triggered, as is the release of eIF2-GDP (guanosine-5’-diphosphate). The large 60S ribosomal subunit is then recruited to form the 80S ribosome, and protein synthesis proceeds to the elongation phase. Recycling of the eIF2-GDP into functional eIF2-GTP is done by eIF2B, a pentameric guanine exchange factor, which is the subject of important regulation by stress kinase as discussed below.

#### Elongation Phase

To elongate the polypeptide chain, amino-acyl tRNAs are brought to the ribosome by pairing the anti-codon of the tRNA with the codon of the mRNA. Several eukaryotic elongation factors (eEFs) are responsible for the execution of this phase. eEF1A and eEF1B are involved in recruitment of amino acyl-tRNAs to the ribosome. eEF2 affects translocation of the ribosome along the RNA after

---

**Fig. 1.** Hypophosphorylated 4E-BP1 has a strong affinity for eIF4E, the cap-binding factor, and prevents its interaction with eIF4G and the recruitment of the other eIFs, thus inhibiting translation initiation. In response to intra- or extracellular stimuli, 4E-BP1 is phosphorylated by mTOR and frees eIF4E, which promotes the formation of the eIF4F complex (composed of eIF4E, 4G and 4A) and translation initiation.
the peptide bond between adjacent amino acids has formed. The rate of the elongation phase is controlled through eEF2, which can be phosphorylated and inactivated by eEF2K (eEF2 kinase). The eEF2K is itself under the control of the signal-dependent mammalian target of rapamycin (mTOR) pathway (fig. 4).

**Termination Phase**

Three eukaryotic release factors (eRFs) facilitate the release of the peptide chain and the 40S and 60S subunits of the ribosome, after the complex encounters the stop codon. Release of the mRNA-bound ribosomes is important as ribosome recycling is a crucial process required to initiate new rounds of translation. This process is highly controlled as reformation of the 80S ribosome is prevented by the eukaryotic initiation factor 6 (eIF6) factor. The eIF6 was initially shown to be a link between extracellular stimuli and the activity of the 60S ribosomal subunit. It associates with the 60S ribosome to prevent its binding to the 40S subunit and blocks translation initiation [4]. Other important functions of eIF6 in translation control have since emerged such as miR silencing through the RNA-induced silencing complex (RISC), which depends on the presence of eIF6 [5].

**General Control of Translation**

Translation is a highly regulated process, allowing the cell to respond promptly to environmental changes. Control of translation is achieved at several levels through mechanisms that affect either specific mRNAs (i.e. mRNAs with specific features/sequences) or all mRNAs at once (nonspecific control). The specificity of a transcript generally depends on its 5'UTR (untranslated region) and 3'UTR. Features (sequence as well as structure) within the 5'UTR of a transcript determine if it will be translated by a cap-dependent or -independent mechanisms (see below) while the specific miRNA-binding sites within the 3'UTR of a transcript can block its translation if the corresponding miRs are expressed. Alternatively, the same pathway/molecule can act on specific mRNAs and on general translation by different mechanisms (mixed control). As an example, the mTOR pathway acts specifically on promoting cap-dependent translation and elongation when activated. Finally, several specific mechanisms of control can interact, such as miR and cap-dependent translation, to control and fine-tune the composition of the proteome.

**Cap-Dependent Translation**

The efficiency of cap-dependent translation is influenced by the complexity of the 5'UTR, as the scanning model predicts that long, GC-rich, highly structured 5'UTRs prevent efficient translation. Scanning efficiency is greatly influenced by the negative free energy (stability) of the hairpins and their position relative to the 5' cap [6].

Cap-dependent mRNAs with uncomplicated UTRs are easily translated because not much energy is required to unwind the 5'UTR and ribosomes freely scan the RNA to find the starting codon. Among the transcripts translated through the cap-dependent mechanism, only about 10% of them have unusually complicated 5'UTRs [7]. For these, activity of ATP-dependent helicases is needed for unwinding these inhibitory secondary structures. Translation initiation of complex and highly structured mRNAs can be controlled by a signal-dependent cascade, the mTOR pathway. In addition, the MAPK (mitogen-activated protein kinase) ERK (extracellular signal-regulated kinase) can also regulate the phosphorylation of 4E-BP1 and appears to be downstream of PI3K [9].

**Cap-Independent Translation**

About 3% of cellular mRNAs have features in their 5'UTRs that allow assembly of the translation initiation machinery near or at the start codon, abolishing the need for formation of a cap-dependent initiation complex and scanning [10]. These features, called internal ribosome entry sites (IRESs), have no similarity in primary or secondary structures; yet, they allow initiation directly at the start codon. Besides the cap-dependent and IRES-mediated translation initiation, a very small number (0.1 to 1%) of mRNAs are translated via re-initiation. These mRNAs contain one or several upstream open reading frames (ORFs, uORFs), which usually do not generate a functional product. For the main ORF to be translated, it must survive the first termination event in order to be re-initiated (for review, see [11, 12]). In response to cellular stress, cap-dependent translation is often shut-down and cap-independent translation, IRES and uORF, is increased allowing the cell to survive (for reviews, see [13–16]).

**Activation of Stress Kinases and the Switch from Cap-Dependent to Cap-Independent Translation**

Many cell stressors (e.g. heat, viral infection, nutrient limitations, endoplasmic reticulum (ER) stress, ultraviolet radiation) shut down protein synthesis by activating one of the eIF2 kinases (eIF2K), which phosphorylates eIF2, and blocks the guanine-exchange factor eIF2B
Phosphorylation of eIF2 reduces general (cap-dependent) translation to about 25% of control levels. When global protein synthesis is shut down, energy is conserved, and upregulation of specific proteins allows the cell to respond and adapt to stress. This general reprogramming of mRNA translation is an integral part of the cellular response to stress [15, 16]. Activation of the stress kinases is a mechanism that stops general protein synthesis, without distinction, generating a survival response. This response is also characterized by formation of stress granules, which are the sites that contain the stalled mRNAs [15, 16]. If translation is reactivated, mRNAs can shuffle out of the stress granules to be translated again [2, 16, 17].

The mTOR Pathway in Protein Translation
The mTOR cascade is a signal-dependent pathway that responds to a variety of stimuli ranging from growth factors and mitogens, which activate the cascade and stimulate cap-dependent translation, to amino-acid deprivation and hypoxic stress, which down-regulate this pathway and lead to a reduction in global protein synthesis. For example, activation of the PI3K (phosphoinositide-3 kinase)/Akt (protein kinase B) pathway activation by insulin or other growth factors activates mTOR (for details, see fig. 3), which in turn leads to phosphorylation of the translational inhibitor, 4E-BP1 (eukaryotic translation initiation factor 4E-binding protein 1), and the p70S6 (p70-ribosomal S6) kinase, resulting in increased translation initiation of highly structured cap-dependent mRNAs (fig. 4). The mTOR cascade also controls translation by affecting initiation of 5’-terminal oligopyrimidine tracts (5’ TOP) mRNAs and translation elongation (fig. 4). Studies in Drosophila, Caenorhabditis elegans, and mammalian cells suggest that tightly controlled processes such as mitosis or resistance to oxidative, osmotic, hypoxic and apoptotic stresses all involve down-regulation of the mTOR cascade [18–21]. When global protein synthesis is shut down, specific cap-independent mRNAs are translated that are critical to the adaptive cellular response. In several disease states, over-activation of the mTOR pathway has been demonstrated, leading to physiological imbalance and higher than normal protein synthesis. While overactivation of mTOR activity would affect primarily mRNAs with a complicated 5’UTR through activation of the RNA helicase eIF4A and eIF4E (fig. 4), general translation would also benefit through activation of the elongation factor eEF2 and 5’TOP mRNAs. In contrast, down-regulation of the mTOR cascade inhibits primarily the cap-dependent translation, whereas mRNAs with an IRES or uncomplicated 5’UTRs are still expressed [22].

Micro-RNA-Regulated Translation
Translation can also be regulated at the 3’UTR side of mRNAs by miRs, which are non-coding, single-stranded RNA molecules ranging from 18 to 27 nucleotides in length that bind to specific sequences in the mRNA. It is predicted that about 30% of human genes are regulated by miRs, which can target specific mRNAs for translational repression by inhibiting the early steps of initiation [23, 24]. miRs have also been implicated in the cellular stress response and often, stress-induced reprogramming of translation up-regulates transcription of miRs, which have been called ‘safeguards against turmoil’ [1, 16]. The nascent transcripts are processed into mature...
Fig. 3. Activation of PI3K by extracellular signals leads to the production of the lipid second messenger phosphatidylinositol-3,4,5-triphosphate (PIP3) from phosphatidylinositol 4,5-bisphosphate (PIP2) in the membrane. Among other things, PIP3 translocates Akt to the membrane where it becomes phosphorylated in its activation loop at Thr 308. Activated Akt is able to release mTOR inhibition by phosphorylating the endogenous mTORC1 inhibitor, proline-rich Akt substrate 40 (PRAS40) [103], and by phosphorylation of tuberous sclerosis protein TSC2 (tuberin), which is in an inhibitory complex with TSC1 (hamartin). The mTOR signaling network consists of two major complexes, mTORC1, which regulates protein synthesis, cell growth and autophagy, and mTORC2 (not pictured), which regulates cytoskeletal organization. The mTORC1 complex is rapamycin-sensitive while mTORC2 is only rapamycin-sensitive after prolonged exposure [104]. After activation, mTORC2 is able to phosphorylate Akt on Ser 473 (for reviews, see [105, 106]). The PTEN (phosphatase and tensin homolog deleted on chromosome ten) tumor suppressor protein regulates PI3K signaling by dephosphorylating the lipid signaling intermediate PIP3 [107].

Fig. 4. Activated PI3K signaling or activated p70S6 kinase [108] phosphorylate the mTOR kinase, which then activates p70S6 kinase. In turn, this phosphorylates and activates eIF4B, which stimulates the helicase activity of the eIF4A, the helicase that unwinds inhibitory secondary structures in the 5’UTR of mRNAs. Phosphorylation of the p70S6K has three additional effects. First, phosphorylation of the ribosomal protein rpS6, a component of the 40S ribosome. In addition, although this issue is controversial [109, 110], p70S6K is thought to control the translation of mRNAs containing oligopyrimidine tracts in their 5’UTR (5’ TOP), mostly mRNAs encoding for components of the translation machinery. Second, phosphorylation of the eukaryotic elongation factor 2 kinase (eEF2K) stimulates the translation elongation phase (for reviews, see [105, 107, 111, 112]). Third, the tumor suppressor programmed cell death 4 (PDCD4), which also regulates eIF4A activity, is a target of the mTOR pathway via the p70S6K. PDCD4 is able to bind the eIF4A helicase and block the translation of mRNAs with highly structured 5’UTRs, while phosphorylated PDCD4 is rapidly degraded by ubiquitination and the eIF4A helicase is released [113]. As mentioned in figure 1, in response to mTOR activation, 4E-BP1 is phosphorylated and frees eIF4E, which promotes translation initiation.
miRs in a two-step process by the RNase enzymes, Drosha and Dicer, into pre-miRs, and then into the mature miRs. miRs bind to specific sequences, generally in the 3’ UTR of target mRNA, via their conserved seed sequence. Mature miRs and argonaute (AGO) proteins then associate into the RNA interference effector complex (RISC) and target-specific mRNAs either for translational repression or for degradation depending on the complementarity of the seed sequence [25]. Translation repression by miR likely blocks the initiation step [23]. Alternatively, a postinitiation mechanism may also contribute, as miR-repressed constructs are associated with heavy microribonucleoproteins that co-sediment with ribosomes, as miR-repressed constructs are associated with heavy microribonucleoproteins that co-sediment with ribosomes [26]. These mechanisms and their implications for translation are discussed in detail elsewhere [27]. Repressed mRNA-miR complexes become localized in stress granules, which are sites where stalled mRNA-polyribosomes accumulate when translation initiation is inhibited [1, 17]. Stress granules assemble upon phosphorylation of eIF2 by one of the stress kinases (eIF2α); yet, they are able to dissemble rapidly in response to changing conditions [1]. Several factors, such as SMAD, lin-28 and hnRNPA1 (heterogeneous nuclear ribonucleoprotein A1), alter the processing of the nascent miR transcripts, and therefore have an indirect effect on translation [28].

Finally these key pathways and proteins allow for tight control of the responses to acute and chronic perturbants that result in a change in the cell phenotype and function through changes in the global amount of protein that is produced. As the condition surrounding the cells changes, protein synthesis is modified in response and often a switch from cap-dependent to cap-independent translation accompanies a change in miR expression which further fine-tunes the composition of the proteome. Specific examples of complex control of protein translation as they relate to the kidney are discussed below.

**Effects of Translation on Kidney Function and Diseases**

The kidney is a highly metabolically active organ, subject to oxidative stress, exposure to a variety of toxins, and physiological needs that require changes in patterns and rates of protein synthesis. Stressors are known to halt general cap-dependent protein synthesis, in order to conserve energy and allow the cell to survive, as well as to increase cap-independent translation of protein crucial to the survival mechanism. Stress kinases play an important role in kidney diseases. When activated, they impair general protein production while allowing only specific proteins to be made. They also trigger formation of the stress granules where upregulated miRs and their stalled target mRNAs are stored, depleting the kidney of critically important proteins.

**Diabetic Nephropathy**

Diabetic nephropathy (DN), a major cause of end-stage kidney disease, is characterized by glomerular basement membrane (GBM) thickening and mesangial matrix expansion, which leads to glomerulosclerosis, tubulointerstitial fibrosis and loss of kidney function. In some cases, enhanced gene transcription correlates with the increase in a specific protein, but in other cases there is a disassociation between mRNA and protein levels. Recognition of this disassociation has prompted evaluation of the role of control of protein translation in both the change in amount and composition of proteins in the kidney in diabetes [29–33]. Several mechanisms controlling protein synthesis are intricately implicated in the different phases that accompany the evolution of DN. After a certain stress threshold is achieved, there is a switch from cap-dependent to cap-independent translation as the mTOR cascade is downregulated and the stress kinases are up-regulated. Proteins important for survival are still translated, but other proteins that are critical for kidney function might be missing. This shift from cap-dependent to cap-independent translation happens at about 30 days after diabetes induction in the rat kidney, and is likely due to upregulation of oxidative [34] and endoplasmic reticulum (ER) stress [35, 36], both of which are implicated in the pathogenesis of DN. miRs are also upregulated, adding to the dysregulation of the pathway controlling translation (mTOR) or downregulating crucial proteins for kidney function.

**Cap-Dependent and Cap-Independent Mechanisms in DN**

In the rat kidney, the first month following diabetes induction is characterized by renal hypertrophy, which correlates with glucose-mediated increases in activation of the mTOR pathway and increases in cap-dependent protein synthesis. The early phase can be attenuated by treatment with rapamycin, a specific inhibitor of mTOR. When rapamycin treatment is started as early as 2 days after induction of diabetes by streptozotocin (STZ), mTOR activation is blocked and glomerular and whole-kidney hypertrophy are prevented despite continued hyperglycemia [37, 38]. This suggests that mTOR pathway...
activation is involved in the early initiation of DN. These findings contrast with the observation that mTOR kinase activity is reduced after 4 weeks of hyperglycemia [39], suggesting that persistent exposure to oxidative [34] and ER stresses might induce compensatory responses [35, 36] that downregulate cap-dependent protein synthesis [14]. After 30 days, there is a switch between downregulation of cap-dependent translation and upregulation of translation by cap-independent mechanisms, as transcripts that contain uORFs and IRES in their 5'UTR are actively translated [40–42]. This leads to a shift in the composition of the proteins that are over-expressed. For example, hyperglycemia is known to upregulate fibroblast growth factor-2, which bears an IRES in its 5'UTR [40, 41, 43, 44]. Similarly, high glucose leads to translation of CD36, a scavenger receptor that mediates uptake of oxidized low-density lipoprotein, via ribosome re-initiation [42, 45]. Whether CD36 re-initiation is regulated via eIF2 or not is not known [46]. Among the ECM (extracellular matrix) proteins increased in DN, laminin-β1 (lamb1) [47, 48] translation is stimulated by hyperglycemia by an IRES-driven mechanism [49].

In animal models of type 2 diabetes (db/db mice, with hyperglycemia and hyperinsulinemia) or in STZ-induced diabetic animals treated with insulin, the mTOR pathway is activated, as insulin is a potent activator of the mTOR cascade [50]. This activation is most likely to occur on the top of the changes described above (activation of the cap-independent translation) as oxidative and ER stresses are still present in DN occurring from type 2 diabetes or in STZ-induced diabetic animals treated with insulin. Long-term or late benefits of rapamycin treatment [51–53] in type 2 models or those treated with insulin are likely mediated in part by blocking these well-known effects of insulin on mTOR; however, the consequences of other factors that also stimulate mTOR would likewise be affected. As an example, high glucose and high insulin were shown to activate the mTOR cascade and phosphorylation of the eEF2 kinase to stimulate the translation elongation phase and more specifically translation of laminin-β1 [31, 32].

Role of miRs in DN
Several miRs are increased in mesangial cells and animal models of DN by chronic high-glucose treatment. Glucose-mediated up-regulation of miR-377 indirectly leads to increased fibronectin production via down-regulation of superoxide dismutases (SODs) and p21-activated kinase, which normally inhibit ECM production [54]. Moreover, the reduction of both SOD1 and SOD2 by miR-377 enhances oxidative stress in mesangial cells [54]. Similarly, HG-mediated increases in transforming growth factor-β (TGFβ) leads to upregulation of miR-192, which indirectly increases collagen via inhibition of an E-box repressor [55]. Although to date the majority of studies of DN have focused on factors that lead to ECM accumulation by upregulation of miRs [54, 55], reductions in critically important proteins via direct miR interaction may also contribute to organ dysfunction and disease progression. As such, overexpression of TGFβ1 in mice upregulated miR-23b, which directly reduced the expression of podocyte proteins, WT1 (Wilms tumor 1), nephrin and podocin, that are important to normal function of the filtration barrier [28]. Similarly, 5–6 weeks after diabetes induction, the laminin-β2 (lamb2) protein, a heterotrimeric matrix glycoprotein, which is a critical component of the GBM, is greatly reduced [56], at a time when the mTOR pathway is thought to be inactive if no insulin is present [39]. As the lamb2 3'UTR has a putative miR-377 binding site, glucose-mediated increases in expression of miR-377, as shown by [54], could be responsible for the reduction in laminin-β2 translation in vitro [57]. Given that loss of laminin-β2, either in null-mutant mice or humans with Pierson's syndrome [58–61] results in significant proteinuria, reductions in critically important proteins such as laminin-β2 via translational regulation might contribute to the development of proteinuria in diabetic nephropathy [62].

Recently, in animals with type 2 diabetes, miRs have been implicated in a mechanism that can mediate prolonged activation of the mTOR pathway. Kato et al. [55, 63, 64] demonstrated that miR-192, which inhibits translation of an E-box repressor, mediates the transcriptional upregulation, not only of collagen as discussed earlier, but also of miR-216a and miR-217. The same group also elegantly demonstrated in mesangial cells in vitro and in DN in vivo that high glucose-associated TGFβ-stimulated production of miR-216a and miR-217 inhibited the translation of PTEN (phosphatase and tensin homologue) [64]. In turn, loss of PTEN results in the constant activation of Akt [64] and therefore drives activation of the mTOR cascade. This results in persistent increases in protein synthesis in the kidney and leads to a change in the composition of the proteome. This suggests that the same miRs are likely to be regulated and contributing to similar changes in DN in both DM1 and DM2.

It is likely that the next crucial steps in understanding the mechanisms underlying increases and decreases in expression of critical proteins in the diabetic kidney will involve direct regulation by miRs. Alterations in both
glucose and insulin levels can impact cap-dependent, as well as cap-independent translation, alter mTOR cascade activity and modulate miRs. Depending on the pathways that are affected and the specific mechanisms involved, alterations in regulation of translation of individual mRNAs will lead to a change in both the amount and composition of proteins expressed in the kidney [65–68]. This will have important implications for understanding the pathogenesis of DN.

Renal Cancer

Cancer arises from defects in control of cell proliferation. During normal mitosis, protein synthesis is tightly regulated through a switch from cap-dependent to cap-independent (IRES-mediated) translation, which is required for controlled cell division [69]. This switch depends on downregulation of the mTOR pathway, as well as inhibition of a target of mTOR, eIF4B, by a mTOR-independent mechanism [69]. Contrary to DN, the mTOR cascade is permanently hyperactivated in renal cell cancer (RCC) [70]. Moreover, cancer cells acquire migratory and invasive properties as they undergo epithelial to mesenchymal transition (EMT), a process that is characterized by loss of cell-cell contacts [71]. miRs influence this process through reduced translation of E-cadherin, the protein that mediates formation of cell-cell contacts.

Cap-Dependent and Cap-Independent Mechanisms in RCC

In normal, noncancerous cells, general cap-dependent protein synthesis is halted during mitosis and several proteins, including the RNA helicase eIF4A, eIF4B and a tumor suppressor, which regulates eIF4A activity (Programmed Cell Death 4, PDCD4), participate in this crucial mechanism (fig. 4). Both eIF4B and the tumor suppressor, PDCD4, are targets of the mTOR pathway via the p70S6K (fig. 4). Phosphorylation of the tumor suppressor PDCD4 releases eIF4A from PDCD4’s inhibitory grip, while phosphorylation of eIF4B stimulates the helicase activity of eIF4A. This cascade must be down-regulated to halt cap-dependent translation and for normal mitosis to occur. If the mTOR pathway is still active during mitosis, the switch form cap-dependent to cap-independent translation does not happen and cells become transformed as if eIF4E were overexpressed [72]. Additionally, in RCC, activation of mTOR [70] leads to translational upregulation of HIF-α (hypoxia-inducible factor alpha) and VEGF (vascular endothelial growth factor) [73, 74] that contribute to cancer progression by promoting angiogenesis. In RCC, as well as in a multitude of other cancers, the mTOR pathway is hyper-activated, although the mechanisms leading to this activation in cancer are not entirely understood [70, 75].

Blockade of mTOR activation with rapamycin has shown promising results in the treatment of advanced RCC [75]. Although nanomolar concentrations of rapamycin or its analogs can reduce mTOR activity, micromolar concentrations have additional effects on phosphorylation of eEF2 and eIF2 that decrease the elongation rate and lead to profound inhibition of global protein synthesis [75, 76]. RCC patients that received the highest weekly dose of the rapamycin analog, CCI-779, had better survival than those in the lower dosage group [76]. Statins, which block mTOR activation by reducing p70S6K phosphorylation and block cap-dependent initiation of translation through up-regulation of PDCD4, have also shown promising results [77]. Both of these approaches to the treatment of RCC suggest that greater inhibition of global protein synthesis than just inhibition of transcripts directly regulated by the mTOR cascade provides added benefit in reducing cell proliferation.

Role of miRs in RCC

Changes in levels of miRs that have direct effects, as well as effects through modulation of the mTOR pathway, have been reported in RCC. In a genomewide screen, miR-141 and miR-200c were found to be down-regulated in RCC compared to normal tissues [78]. Downregulation of these miRs led to up-regulation of one of the miR-141/200c targets, ZEB2 (zinc finger E-box binding homeobox 2), which normally functions as a transcriptional repressor that inhibits E-cadherin expression [78]. Loss of E-cadherin is an indicator that cells have undergone EMT, which correlates with metastatic disease and a poor prognosis in RCC [79, 80]. E2F3, a transcription factor that regulates genes that control progression through the cell cycle, is reduced in RCC as a result of miR-34a-mediated inhibition of translation [81]. Additional effects on protein translation result from changes to mTOR pathway activation that are influenced by miR-mediated alterations in expression levels of mTOR pathway components. Up-regulation of miR-21 in RCC [78] leads to reductions in some miR-21 targets such as PTEN and PDCD4. As discussed above, loss of PTEN hyperactivates mTOR through Akt, which then stimulates protein synthesis and leads to the transformation of cells through dysregulation of mitosis. Downregulation of the tumor suppressor, PDCD4, releases the RNA helicase, eIF4A, which leads to activation of translation of mRNAs with complicated 5’UTRs. These effects alter the amount and
composition of the proteins that are expressed by RCC cells without any need for growth factors or other upstream activators.

Alterations in several key steps in control of cell proliferation are needed for a cell to become cancerous and metastasize; however, there is growing evidence that dysregulation of translational control is a common feature in cancer, and that control is disrupted by abnormalities in mTOR pathway activation or miR-mediated regulation of specific proteins.

Polycystic Kidney Disease

Polycystic kidney disease (PKD) leads to end-stage kidney failure as a result of progressive growth of renal cysts [82, 83]. Although specific gene mutations have been identified in clinical subtypes of PDK (PKD1, PKD2, PKHD1), the mechanisms that lead to cyst formation and growth are poorly understood. Mutations in all three genes have been linked to processes that affect cell growth (cell size and protein content) and cell proliferation (dysregulation of cell division); yet, details of these mechanisms are just beginning to emerge. Similar to RCC, the mTOR cascade is hyperactivated and miR-21 has been shown to be upregulated.

Cap-Dependent and Cap-Independent Mechanisms in PKD

The polycystin-1 (PKD1) gene product is a receptor-like transmembrane protein with a large intracellular cytoplasmic tail. When polycystin-1 is mutated or inactivated in PKD patients or in animal models of PKD, mTOR pathway activity is increased in renal cysts as compared to controls [84]. It was shown that the cytoplasmic tail of PKD1 interacts with TSC2/tuberin (tuberous sclerosis complex 2, TSC2), a key negative regulator of the mTOR pathway [83] and PDK1 mutants are similar to TSC2 mutations (leading to tuberous sclerosis) which also consists of renal cysts and benign tumors in multiple organs. In a similar way, fibrocystin defects are also associated with activation of the mTOR cascade [85], although the molecular components of the fibrocystin (PKHD1) pathway are not as well defined. In a rat model of PKD, increased activation of the mTOR pathway was treated successfully with rapamycin [86–88] as the resultant decrease in protein synthesis was accompanied by a reduction in the rate of cyst growth.

Several mechanisms other than mTOR exist to ensure that global protein synthesis is shut down during the cell cycle, including activation of the stress kinases (eIF2K). This provides a greater inhibition of global protein synthesis than just inhibition of the mTOR cascade. The protein polycystin-2 (PKD2) is a calcium-regulated, calcium-permeable ion channel located on the endoplasmic reticulum membrane. The wild-type polycystin-2 ensures a slow-down of general protein synthesis by promoting eIF2 phosphorylation through PERK (PKR-like ER kinase) activation while mutations of polycystin-2 lead to uncontrolled cell proliferation [89] as PERK is not activated and protein synthesis is not inhibited.

Role of miRs in PKD

A few studies have examined the relation between miR dysregulation and PKD [90, 91], but only one related to the kidney [91]. Pandey et al. [91] found 30 dysregulated miRs in the kidneys of a rat model of PKD. Surprisingly, of 30 miRs that were differentially regulated, only miR-21 was upregulated [91]. In RCC, miR-21 was shown to target the tumor suppressors PTEN and PDCD4, and thus to enhance activation of the mTOR cascade [78]. Along with the mechanisms described above, this would enhance protein translation and cyst growth. The miRs that were reduced might similarly promote enhanced translation of their targets, as miR-mediated reductions in translation would be lost.

In summary, PKD is characterized by uncontrolled protein translation during cell division, which is a time when inhibition of global translation is usually necessary. This occurs either by inappropriate activation of the mTOR cascade by polycystin-1 or fibrocystin mutants, or by failed PERK activation by polycystin-2 mutants. Changes in miR are also predicted to lead to enhanced protein synthesis through both direct effects on mRNA targets (such as inhibition of PDC4, as well as indirect effects through modulation of mTOR activity (such as inhibition of PTEN). Dysregulated protein synthesis in PKD leads to cell growth and proliferation, which drive cyst expansion; thus, therapies that target control of protein translation may impact the rate of progression of these genetic disorders.

Nephritis

In immune-mediated forms of chronic nephritis, persistent activation of the inflammatory response leads to progressive fibrosis. As in other disorders, many inflammatory mediators activate the mTOR pathway and through mechanisms described above impact the composition and amount of proteins that accumulate in the kidney.
Cap-Dependent and Cap-Independent Mechanisms in Nephritis

In inflammatory syndromes, activation of protein synthesis is a common phenomenon, and the mTOR pathway is particularly implicated in the control of cytokine production. This has been confirmed in human and mouse lupus nephritis [92], and anti-Thy1.1-induced chronic glomerulosclerosis in the rat [93, 94]. Support for the importance of mTOR activation in the Thy1.1 model comes from studies in which inhibition of mTOR with rapamycin attenuates matrix accumulation, reduces proteinuria, and reduces cell proliferation [93, 94].

Despite the hyperactivation of the mTOR-dependent transcripts in several cases of nephritis (see above), several studies have shown that endogenous attenuation of protein synthesis was achieved, via activation of PERK and phosphorylation of eIF2, in several models of nephritis, as a protection mechanism [36, 95–98]. Similarly, in an in vivo model of C5b-9-induced glomerular epithelial cell injury, phosphorylation (and activation) of PERK, and eIF2, consequently, were significantly enhanced compared to control, and global protein synthesis was suppressed [96]. This ER-stress response, due to the attack by the complement, is a mechanism of defense to protect the cells and downregulate cap-dependent protein synthesis. As is often the case, when general cap-dependent translation is reduced, cap-independent translation is increased for genes that are critical to kidney function. As an example, nephrin is a critical slit diaphragm protein involved in maintaining the filtration barrier [96] and its translation is maintained through the cap-independent translation up-regulation: the nephrin 5’UTR mRNA, which has several uORFs, was shown to be up-regulated, when the ER-stress response was activated and PERK was phosphorylated [96].

Role of miRs in Nephritis

During a normal inflammatory response, modulation of miRs leads to cytokine production, which when it becomes persistent can lead to organ damage [99]. In mice, overexpression of the miR-17–92 cluster in lymphocytes leads to a lymphoproliferative disorder and autoimmune kidney disease with enlarged glomeruli, mesangial expansion, and proteinuria [100]. IL-6, a potent mediator of renal fibrosis, can activate expression of the miR-17/92 cluster [101]. Overexpression of this cluster reduces the translation of PTEN, which then leads to overactivation of the PI3K/Akt/mTOR pathway [100]. Dysregulation of the PI3K/Akt cascade has been shown to be a major component of kidney disease [102].

Conclusion

Proper control of protein synthesis is crucial for the cell’s normal functions. In all four examples of kidney disease, DN, RCC, PKD and nephritis, hyperactivation of the mTOR pathway which leads to higher rates of protein synthesis is a crucial piece of the puzzle. In many forms of kidney disease this would be expected to contribute to the chronic fibrosis that ultimately compromises kidney function. Yet, activation of stress kinases leads to the opposite response by decreasing general protein synthesis (mTOR controlled), as well as mediating upregulation of the cap-independent translation of transcripts. This switch can result in down-regulation of critical proteins while others are upregulated. Although these changes may protect cell survival in the short run, they become maladaptive and contribute to disease progression in the long run. Current research has shown disease associations with specific regulation of individual components of the systems that regulate protein translation; yet given its complexity, considerable work needs to be done to understand how different components interact to increase some proteins, decrease others and produce a significantly modified proteome that promotes disease progression.

Acknowledgements

We thank Dr. David R. Morris and Kim Hansen for critical reading of the manuscript and their helpful suggestions as well as the anonymous reviewers for their helpful criticisms. This material is the result of work supported with resources and the use of facilities at the VA Puget Sound Health Care System, Seattle, Wash., USA. The contents of this report do not represent the views of the Department of Veterans Affairs or the United States Government.

References


Schaefcr/Abrass


66 Li X, Quigg RJ: MicroRNA-377 is up-regulated and can lead to increased fibronectin expression and can lead to increased fibronectin production in diabetic nephropathy: FASEB J 2008;22:4126–4135.


69 Sivan G, Elroy-Stein O: Regulation of mRNA translation are responsible for impaired IgFbp-5-mediated mesangial cell migration in the presence of high glucose. Am J Physiol Renal Physiol 2009;in press.


Translational Control in the Kidney

Am J Nephrol 2010;31:189–201

201